Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0091 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0091 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
filingDate |
2016-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ad66f0eaf4cdc6090cfcea62f648bac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09fc4ac0c4e08cf51f4d4e410ec498d2 |
publicationDate |
2019-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-109121421-A |
titleOfInvention |
Gene therapy for the treatment of familial hypercholesterolemia |
abstract |
Provided are compositions and regimens useful for reducing one or more of LDL-cholesterol, total cholesterol and/or fasting triglycerides in a subject, and/or reducing LDL apolipoprotein B (apoB) ) of the fractional decomposition rate (FCR) changed from baseline to selected time points after rAAV administration. The method involves administering a suspension of replication-deficient recombinant adeno-associated virus (rAAV) to a human subject by infusion via a peripheral vein. |
priorityDate |
2015-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |